PE20020529A1 - Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento - Google Patents

Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento

Info

Publication number
PE20020529A1
PE20020529A1 PE2001001148A PE2001001148A PE20020529A1 PE 20020529 A1 PE20020529 A1 PE 20020529A1 PE 2001001148 A PE2001001148 A PE 2001001148A PE 2001001148 A PE2001001148 A PE 2001001148A PE 20020529 A1 PE20020529 A1 PE 20020529A1
Authority
PE
Peru
Prior art keywords
coating
coating layer
poly
methacrylic acid
interior
Prior art date
Application number
PE2001001148A
Other languages
English (en)
Inventor
Gregory Paul Ditimar
Joseph Michael Amante
Tony Ryan Cronk
Daniel Gary Newby
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22954700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020529(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20020529A1 publication Critical patent/PE20020529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN AGENTE TERAPEUTICAMENTE ACTIVO; b) UNA CAPA DE RECUBRIMIENTO INTERIOR SELECCIONADA DE POLI(ACIDO METACRILICO, METIL METACRILATO) 1:2, POLI(ACIDO METACRILICO, METIL METACRILATO) 1:1 Y MEZCLAS DE ESTOS Y c) UNA CAPA DE RECUBRIMIENTO EXTERIOR QUE COMPRENDE UN MATERIAL DE RECUBRIMIENTO DE POLIMERO ENTERICO O DE PELICULA DONDE LA CAPA INTERIOR NO ES LA MISMA QUE LA CAPA EXTERIOR, EN DONDE SI LA CAPA DE RECUBRIMIENTO INTERIOR ES POLI(ACIDO METACRILICO, METIL METACRILATO) 1:1 ENTONCES LA CAPA DE RECUBRIMIENTO EXTERIOR NO ES Y POLI(ACIDO METACRILICO, METIL METACRILATO) 1:2. LA CAPA DE RECUBRIMIENTO EXTERIOR SE SELECCIONA DEL GRUPO QUE CONSISTE DE DERIVADOS DE CELULOSA, ESTERES DE CELULOSA, METILCELULOSA, ETILCELULOSA , ENTRE OTROS. EL ESPESOR TOTAL DEL RECUBRIMIENTO DE LAS CAPAS INTERIOR Y EXTERIOR COMBINADAS ES DE 5mg/cm2 Y 40mg/cm2. EL AGENTE TERAPEUTICAMENTE ACTIVO SELECCIONADO DE LAXANTES, ANTIDIARREICOS, ANTIINFLAMATORIOS, ENTRE OTROS. SE REFIERE ADICIONALMENTE PARA MANTENER EL SITIO DE SUMINISTRO DESEADO DE UN AGENTE TERAPEUTICO EN EL TRACTO GASTROINTESTINAL Y FORMAS DE DOSIFICACION FARMACEUTICA CON MULTIPLES RECUBRIMIENTOS PARA REDUCIR EL IMPACTO DE FRACTURAS DEL RECUBRIMIENTO
PE2001001148A 2000-11-20 2001-11-16 Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento PE20020529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25212200P 2000-11-20 2000-11-20

Publications (1)

Publication Number Publication Date
PE20020529A1 true PE20020529A1 (es) 2002-07-18

Family

ID=22954700

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001148A PE20020529A1 (es) 2000-11-20 2001-11-16 Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento

Country Status (3)

Country Link
US (4) US6893662B2 (es)
CA (1) CA2359812C (es)
PE (1) PE20020529A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
WO2004087113A1 (en) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Pharmaceutical compositions for colon specific delivery
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
EP1720536B1 (en) 2004-02-06 2012-04-25 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
AU2005231145B8 (en) 2004-03-31 2010-11-11 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
AR052472A1 (es) * 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
CA2607949C (en) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
US20070277849A1 (en) * 2006-06-06 2007-12-06 Shah Ketan N Method of neutralizing a stain on a surface
US7727289B2 (en) 2005-06-07 2010-06-01 S.C. Johnson & Son, Inc. Composition for application to a surface
US20100154146A1 (en) 2008-07-02 2010-06-24 S.C. Johnson & Son, Inc. Carpet decor and setting solution compositions
US8557758B2 (en) 2005-06-07 2013-10-15 S.C. Johnson & Son, Inc. Devices for applying a colorant to a surface
US8846154B2 (en) 2005-06-07 2014-09-30 S.C. Johnson & Son, Inc. Carpet décor and setting solution compositions
US7776108B2 (en) 2005-06-07 2010-08-17 S.C. Johnson & Son, Inc. Composition for application to a surface
CA2610730C (en) 2005-06-07 2013-04-23 S. C. Johnson & Son, Inc. Method of neutralizing a stain on a surface
US8061269B2 (en) 2008-05-14 2011-11-22 S.C. Johnson & Son, Inc. Multilayer stencils for applying a design to a surface
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2586427A3 (en) * 2005-08-24 2013-05-29 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US20070184111A1 (en) * 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
US20070253927A1 (en) * 2006-04-13 2007-11-01 Gwenaelle Jegou Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US9095512B2 (en) * 2006-08-11 2015-08-04 Asahi Kasei Chemicals Corporation Method for producing spherical base granules comprising hardly water-soluble drug
BRPI0622008A2 (pt) * 2006-09-13 2011-12-20 Procter & Gamble métodos de tratamento para colite ulcerativa
WO2008033125A1 (en) * 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
CN101534795B (zh) 2006-11-21 2013-04-03 麦克内尔-Ppc股份有限公司 改进释放的镇痛悬浮液
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
WO2008122967A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited An oral pharmaceutical composition
SI2152250T1 (sl) * 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2385826A4 (en) * 2009-01-09 2012-04-04 Mayo Foundation METHODS AND MATERIALS FOR ADMINISTERING BILIARY ACIDS
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
PL2470165T3 (pl) * 2009-08-28 2018-09-28 Hercules Llc Kompozycja otoczkowa ze stałych proszkowych związków
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
EP2953619A1 (en) 2013-03-15 2015-12-16 Warner Chilcott Company, LLC Mesalamine pharmaceutical composition with multiple dosage elements for reduced delivery variability
US20160331689A1 (en) 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
WO2017067685A1 (en) * 2015-10-21 2017-04-27 Capsugel Belgium N.V. Printing process for oral dosage forms
JP2019513800A (ja) * 2016-04-19 2019-05-30 フェリング ベスローテン フェンノートシャップ メサラジンの経口薬学的組成物
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
EP4346858A1 (en) * 2021-06-01 2024-04-10 NBI Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2512247A1 (de) 1975-03-20 1976-10-14 Thomae Gmbh Dr K Gegen feuchtigkeit stabilisierte presslinge mit feuchtigkeitsempfindlichen inhaltsstoffen
US4211777A (en) 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
WO1981002671A1 (en) 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
US4312806A (en) 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DE3151196A1 (de) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
JPS58109413A (ja) 1981-12-23 1983-06-29 Eisai Co Ltd 耐衝撃性腸溶錠
JPS58213073A (ja) 1982-06-07 1983-12-10 Masatoshi Yamada 油状物質の固形化法
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
SE457505B (sv) 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4678516A (en) 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
DK153412C (da) 1984-11-22 1988-12-19 Ferring A S Fremgangsmaade til fremstilling af p-aminophenoler ved elektrolyse
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
SE460945B (sv) 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5068110A (en) 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
JP2514078B2 (ja) 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
DE3838094A1 (de) 1988-11-10 1990-05-17 Nordmark Arzneimittel Gmbh Feste pharmazeutische retardform
DE3907973A1 (de) 1989-03-11 1990-09-13 Merck Patent Gmbh Trockenmittel-tablette
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5540945A (en) 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
JPH0383914A (ja) 1989-08-18 1991-04-09 W R Grace & Co ドラッグキャリアー
US5027797A (en) 1989-10-12 1991-07-02 Horace Bullard Apparatus for the movement of blood by external pressure
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5175003A (en) 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5018621A (en) 1990-04-16 1991-05-28 Connell Jr John J O Cylindrical container and dispenser for spherical objects
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5629012A (en) 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
DE69207863T2 (de) 1991-11-13 1996-06-05 Glaxo Canada Vorrichtung zur kontrollierten Wirkstoffreigabe
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5656296A (en) 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5837277A (en) 1992-06-04 1998-11-17 Smithkline Beecham Corporation Palatable pharmaceutical compositions
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
DE69332082T2 (de) 1992-11-06 2003-02-06 Hisamitsu Pharmaceutical Co., Inc. Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE69425453T2 (de) 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
HU213407B (en) 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5536507A (en) 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
DE19511131A1 (de) 1995-03-27 1996-10-02 Basf Ag Mechanisch stabile feste Wirkstoffzubereitungsformen
WO1996030003A1 (de) 1995-03-30 1996-10-03 Werner Kreutz Arzneistoffe zur selektiven bekämpfung von tumorgewebe
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5631245A (en) 1995-06-06 1997-05-20 Biodynamics Pharmaceuticals, Inc. Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds for treating the pathology of adverse inflammatory reactions
US5656294A (en) 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
FR2738150B1 (fr) 1995-09-01 1997-10-31 Synthelabo Utilisation de la sulphasalazine et de ses metabolites pour la fabrication d'un medicament utile dans le traitement de l'insuffisance veineuse et des ulceres veineux
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
US6004581A (en) 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
PT871434E (pt) 1995-12-21 2002-02-28 Ferring Farma Lab Composicao farmaceutica oral de libertacao modificada contendo 5-asa e processo para o tratamento de doencas do intestino
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
EP0918513B1 (de) 1996-08-15 2000-12-06 Losan Pharma GmbH Gut schluckbare orale arzneiform
CA2279651A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CN1239425A (zh) 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
WO1998026767A2 (en) 1996-12-17 1998-06-25 Poli Industria Chimica S.P.A. Site-specific controlled release dosage formulation for mesalamine
WO1998027967A1 (en) 1996-12-20 1998-07-02 Dumex-Alpharma A/S Release-controlled coated tablets
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2220038A1 (en) 1998-01-05 1999-07-05 Amina Odidi Device for the delivery of high dose pharmaceutical, neutraceutical, agricultural, biological, and chemical substances
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
GB9810181D0 (en) 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulations
JP2002535353A (ja) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
DK1183014T3 (da) 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IT1318376B1 (it) 2000-03-07 2003-08-25 Pharmatec Internat S R L Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo.
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
DE10013030A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Verwendung eines Copolymers zur Herstellung einer Arzneiform zur Therapie von Colitis ulcerosa und verwendungsgemäße Arzneiform
SE0001151D0 (sv) 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
WO2001091716A1 (en) 2000-05-30 2001-12-06 Add Advanced Drug Delivery Technologies Ag Peroral therapeutic system comprising glipizide
US6365209B2 (en) 2000-06-06 2002-04-02 Capricorn Pharma, Inc. Confectionery compositions and methods of making
DE10029410A1 (de) 2000-06-15 2002-01-03 Bfgoodrich Diamalt Gmbh Verfahren zur Herstellung von 5-Aminosalicylsäure
IT1318625B1 (it) 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
WO2002017887A1 (de) 2000-08-29 2002-03-07 Mepha Ag Arzneimittel zur behandlung von darmerkrankungen
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20030175349A1 (en) 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
ATE380022T1 (de) 2001-01-31 2007-12-15 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
CA2444569C (en) 2001-04-18 2011-01-04 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US20070059368A1 (en) 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003020242A1 (en) 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR036797A1 (es) 2001-10-15 2004-10-06 Ferring Bv Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
EP1453487B2 (en) 2001-11-23 2021-03-31 Allergan Pharmaceuticals International Limited Pharmaceutical dosage form with multiple coatings
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
FR2837100B1 (fr) 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
ATE482694T1 (de) 2002-07-05 2010-10-15 Temrel Ltd Zusammensetzung zur kontrollierten wirkstoffabgabe
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10250543A1 (de) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
JP2006520390A (ja) 2003-03-14 2006-09-07 ムルイェ、ニルマル 徐放性錠剤の製造方法
WO2004087113A1 (en) 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Pharmaceutical compositions for colon specific delivery
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
AP2006003585A0 (en) 2003-09-19 2006-04-30 Penwest Pharmaceuticals Co Delayed release dosage forms.
JP4593469B2 (ja) 2003-09-22 2010-12-08 杏林製薬株式会社 変色改善された５−アミノサリチル酸固形製剤およびその保存方法
WO2005030173A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Colon-specific drug delivery using interpolymer complexations
US20050175695A1 (en) 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1547601A1 (en) 2003-12-23 2005-06-29 Ferring B.V. Coating method
FR2872044B1 (fr) 2004-06-28 2007-06-29 Flamel Technologies Sa Formulation pharmaceutique a base d'antibiotique sous forme microcapsulaire
KR20080085924A (ko) 2004-09-01 2008-09-24 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
EP1811975A2 (en) 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
AU2005299748B2 (en) 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
DE602005007624D1 (de) 2004-10-28 2008-07-31 Pantec Ag Herstellung einer rasch zerfallendenden festen darreichungsform ausgehend von einem pulver und einem gefriertrocknungsschritt
FR2878159B1 (fr) 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
US7691364B2 (en) 2005-01-28 2010-04-06 Bezwada Biomedical, Llc Functionalized drugs and polymers derived therefrom
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20090048219A1 (en) 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
US20090017110A1 (en) 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US20060292225A1 (en) 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
WO2007019888A2 (en) 2005-08-12 2007-02-22 Ctg Pharma S.R.L. Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
WO2007020508A1 (en) 2005-08-12 2007-02-22 Ferring International Center S.A. Method and device for dividing granules
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
RU2385712C2 (ru) 2005-08-24 2010-04-10 Рубикон Рисёч Пвт Лтд. Рецептура с контролируемым высвобождением
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US9603941B2 (en) 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
AU2007208998A1 (en) 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
WO2007127488A1 (en) 2006-04-27 2007-11-08 Shenoy Narmada R Compositions and methods for treating or preventing diseases of body passageways
WO2007128349A1 (en) 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
US20080014228A1 (en) 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
WO2008013416A1 (en) 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
WO2008033125A1 (en) 2006-09-13 2008-03-20 The Procter & Gamble Company Methods of treatment for ulcerative colitis using aminosalicylate
BRPI0622008A2 (pt) 2006-09-13 2011-12-20 Procter & Gamble métodos de tratamento para colite ulcerativa
US20080081070A1 (en) 2006-09-15 2008-04-03 Auriga Laboratories, Inc. Pharmaceutical formulation with enhanced solubility for the delivery of corticosteroids
WO2008056200A1 (en) 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
US20100035850A1 (en) 2006-11-17 2010-02-11 Shire Development Inc. Method of treatment for inflammatory bowel disease
US20100179170A1 (en) 2006-12-05 2010-07-15 Lisa Claire Du Toit Heterogeneously configured multiparticulate gastrointestinal drug delivery system
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
US8217083B2 (en) 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20090028944A1 (en) 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2009040818A1 (en) 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
WO2009047802A2 (en) 2007-10-10 2009-04-16 Lupin Limited Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof
US8551720B2 (en) 2007-10-25 2013-10-08 The Board Of Trustees Of Southern Illinois University Methods for diagnosing bowel disease
WO2009078872A1 (en) 2007-12-18 2009-06-25 Soluprin Pharmaceuticals, Inc. Orally disintegrating water soluble analgesic formulations and methods for production thereof
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US20090169622A1 (en) 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
AP2010005341A0 (en) 2008-01-11 2010-08-31 Cipla Ltd Solid pharmaceutical dosage form
EP2133071A1 (en) 2008-06-09 2009-12-16 Université de la Méditerranée Process for making gastroretentive dosage forms
WO2009150530A2 (en) 2008-06-11 2009-12-17 Ferring International Center Sa Novel foam composition
EP2135601A1 (en) 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
WO2009158384A1 (en) 2008-06-27 2009-12-30 The Procter & Gamble Company Methods and kits for the treatment inhibition, and maintenance of gastrointestinal disorders
US20090326069A1 (en) 2008-06-30 2009-12-31 Bltn, Llc Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers

Also Published As

Publication number Publication date
US20140093576A1 (en) 2014-04-03
US20050181053A1 (en) 2005-08-18
CA2359812C (en) 2004-02-10
CA2359812A1 (en) 2002-05-20
US20050169996A1 (en) 2005-08-04
US20020098235A1 (en) 2002-07-25
US8580302B2 (en) 2013-11-12
US6893662B2 (en) 2005-05-17
US9089492B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
PE20020529A1 (es) Forma de dosificacion farmaceutica con multiples recubrimientos para reducir el impacto de fracturas del recubrimiento
ES2272344T3 (es) Preparacion laminar multicapas a base de polimeros hidrofilos para la liberacion rapida de principios activos.
ES2272586T3 (es) Preparacion con vehiculo farmaceutico aplicable a superficies de mucosas.
ES2569354T3 (es) Forma farmacéutica multiparticular, que contiene productos activos de ácido nucleico de formulación mucoadhesiva, así como un procedimiento para la obtención de la forma farmacéutica
IL161628A0 (en) Pharmaceutical dosage form with multiple coatings
ES2355439T3 (es) Parche bioerosionable.
ES2509892T3 (es) Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ES2195342T3 (es) Formulacion farmaceutica de omeprazol.
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
RU2008114352A (ru) Композиции для местного применения
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
JP2007536311A5 (es)
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
DK1161248T3 (da) Farmaceutisk sammensætning indeholdende en nitratkilde og et forsurende middel til behandling af åbne sår og forbrændinger
BRPI0412211A (pt) composições de liberação controlada
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
CL2011000710A1 (es) Combinacion farmaceutica que comprende un inhibidor especifico de smoothened y un inhibidor de cinasa pi3 especifico; y uso en el tratamiento de cancer.
ES2188426B1 (es) Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
AR070017A1 (es) Una composiciones de liberacion prolongada que comprende micofenolato sodico,el metodo de utilizar dicha composicion y el uso de dicha composicion
CO5590913A2 (es) Terapia de combinacion antivirica
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.

Legal Events

Date Code Title Description
FD Application declared void or lapsed